comparemela.com

Page 4 - Ros Deegan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Syncona : OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension

Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and chair of multiple listed biotechs British Patient. | May 15, 2023

United kingdomJames jim geraghtyJim geraghtyGenzyme europeRos deeganCarol robinsonRosamond deeganYale law schoolOxford science enterprisesCanbridge pharmaceuticalsBusiness development at sanofiPrudential regulation authorityBritish patient capitalConsilium strategic communicationsFinancial conduct authorityBritish business bank

OMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio Progress

Move to new purpose-built 16,000ft2 flagship site on ARC Oxford campus to support continued company growthExpansion of senior leadership team with the appointment of Winfried Barchet Ph.D. as Vice President of ImmunologyOxford, United Kingdom – 19 April 2023 – OMass Therapeutics (‘OMass’, or.

United kingdomNordrhein westfalenRos deeganRosamond deeganDavid williamsGerman centre for infection researchConsilium strategic communicationsOxford science enterprisesUniversity of bonnVice presidentExecutive directorInnate immunityTranslational immunologyGerman centreChief executiveNorthpond ventures

Syncona : OMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio Progress

Move to new purpose-built 16,000ft2 flagship site on ARC Oxford campus to support continued company growth Expansion of senior leadership team with the appointment of Winfried. | April 19, 2023

United kingdomNordrhein westfalenDavid williamsRosamond deeganRos deeganUniversity of bonnGerman centre for infection researchConsilium strategic communicationsOxford science enterprisesVice presidentExecutive directorInnate immunityTranslational immunologyGerman centreChief executive officerNorthpond ventures

Novel drug-discovery approach lands big backers

UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare diseases.

Scott billerRos deeganDame carol robinsonDiana bernsteinShouti pharmaceuticalsOxford science enterprisesOxford universityUnited kingdom basedSanofi venturesNorthpond venturesGoogle venturesLaia crespoJeantet prizeFranklin medalWeight lossMedical devices

OMass Therapeutics Raises $100 Million in Series B

PRESS RELEASE OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases Financing led by new.

United statesNew yorkUnited kingdomMountain viewCity ofSan franciscoScott billerRos deeganEdward hodgkinDame carol robinsonDiana bernsteinRosamond deeganOmass odyssSilicon valley bankOxford science enterprisesFlatiron health

vimarsana © 2020. All Rights Reserved.